Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.26) by 146.15 percent. The company reported quarterly sales of $1.990 million which missed the analyst consensus estimate of $16.263 million by 87.76 percent. This is a 88.51 percent decrease over sales of $17.322 million the same period last year.
Cellectis Q4 2023 GAAP EPS $(0.64) Misses $(0.26) Estimate, Sales $1.990M Miss $16.263M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.